Insulin Resistance in Women With Prolactinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00481299|
Recruitment Status : Completed
First Posted : June 1, 2007
Last Update Posted : June 1, 2007
Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.
The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.
|Condition or disease|
|Prolactinoma Insulin Resistance Hyperlipidemia|
|Study Type :||Observational|
|Actual Enrollment :||2004 participants|
|Observational Model:||Defined Population|
|Official Title:||Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists|
|Study Start Date :||October 2004|
|Actual Study Completion Date :||September 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00481299
|Clementino Fraga Filho University Hospital|
|Rio de Janeiro, RJ, Brazil|
|Principal Investigator:||Erika CO Naliato, MSc||Federal University of Rio de Janeiro - Brazil|